Targacept (NASDAQ:TRGT) has $10 million in additional funds to apply toward clinical trials on a drug candidate intended for patients with schizophrenia.
The Winston-Salem, North Carolina biopharmaceutical company last month completed a stock offering that net the company just over $70 million. On Friday, Targacept announced it has completed the sale of an additional 548,780 shares and exercised the over-allotment option granted to the underwriters of the offering. Net proceeds from that stock sale are approximately $10.6 million, which puts Targacept’s total haul at about $80.8 million.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Targacept’s stock offering followed a shelf registration statement last December in which the company gave itself the option to raise up to $150 million to develop its drug candidates. Targacept said most of the proceeds from the May offering will be applied to TC-5619, a compound that showed positive results in mid-stage clinical trials that studied cognitive dysfunction in patients with schizophrenia, but failed in a separate trial that studied attention-deficit/hyperactivity disorder, or ADHD. TC-5619 is also in preclinical studies for Alzheimer’s disease.
Drug partner AstraZeneca (NYSE:AZN) had the option to license the drug candidate under a 2005 partnership agreement to jointly research and develop drug candidates for cognitive disorders. AstraZeneca evaluated the compound but declined to license it and Targacept retained development rights. AstraZeneca remains a partner to Targacept on other compounds in development.
Deutsche Bank Securities Inc. acted as sole book-running manager for the offering. Lazard Capital Markets, Leerink Swann, Oppenheimer & Co., Needham & Company, Ladenburg Thalmann & Co. and Global Hunter Securities acted as co-managers for the offering.